Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Arthritis Rheumatol. 2019 Jan 24;71(3):451–459. doi: 10.1002/art.40727

Figure 3:

Figure 3:

Kaplan-Meier survival analysis comparing flare-free survival throughout the eight-month phase following anti-TNF withdrawal according to elevated vs. normal (A) serum S100A8/A9 and (B) serum S100A12 levels at the time of anti-TNF withdrawal (Hazard ratio per logrank test for S100A8/A9 >690 ng/ml 0.72 (95% CI 0.36–1.42) and for S100A12 >120 ng/ml 1.13 [95% CI 0.55–2.33])